Silo Pharma, Inc. (SILO) - 10-K Summary for Fiscal Year Ended December 31, 2025
Business Context and Reporting Period
Silo Pharma, Inc. is a developmental-stage biopharmaceutical and cryptocurrency company. The reporting period covers the fiscal year ended December 31, 2025. The company operates two primary business lines: (1) developing novel therapeutics for underserved conditions including PTSD, anxiety, fibromyalgia, Alzheimer's disease, and multiple sclerosis; and (2) a cryptocurrency treasury strategy initiated in August 2025 involving the acquisition and staking of digital assets (Bitcoin, Ethereum, Solana).
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $72,102 | $72,102 |
| Net Loss | $(4,227,698) | $(4,392,880) |
| Operating Expenses | $4,308,469 | $4,771,958 |
| Cash and Cash Equivalents | $4,748,700 | $3,905,799 |
| Working Capital | $6,737,542 | $5,455,483 |
| Crypto Assets (Fair Value) | $221,817 | $0 |
| Crypto Assets (Cost) | $98,584 | $0 |
Note: Revenue is derived entirely from license fee amortization. The company has no history of profitable operations.
Material Changes vs. Prior Period
- Operating Expenses: Decreased by approximately $463,000 (9.7%) year-over-year, driven by reductions in compensation, professional fees, and research and development (R&D) costs, partially offset by a $518,250 non-cash expense for acquired software technology.
- Cost of Revenues: Increased significantly from $5,838 to $44,295 due to accelerated amortization of license fees following the termination of the Master License Agreement with the University of Maryland, Baltimore (UMB) in July 2025.
- Crypto Strategy: The company initiated a cryptocurrency treasury strategy in August 2025. This resulted in unrealized losses of $64,608 and impairment losses of $39,916 on crypto assets held at fair value and cost, respectively.
- Liquidity: Working capital increased by $1.28 million, supported by net proceeds of approximately $4.86 million from financing activities (sale of common stock and warrant exercises).
Guidance, Outlook, and Risks
Outlook and Guidance: Management believes current cash and short-term investments are sufficient to meet obligations for at least twelve months. The company aims to submit an Investigational New Drug (IND) application for its lead candidate, SPC-15 (PTSD/anxiety), in 2026. No specific financial guidance was provided.
Material Risks:
- Nasdaq Compliance: The company received a notice of non-compliance with the $1.00 minimum bid price requirement. It was granted an extension until June 22, 2026, to regain compliance, potentially via a reverse stock split.
- Regulatory & Controlled Substances: Significant risks exist regarding the rescheduling of psilocybin (Schedule I) and ketamine (Schedule III) by the DEA, which is required for commercial marketing.
- Cryptocurrency Volatility: The new treasury strategy exposes the company to high price volatility, cybersecurity risks, and potential regulatory classification of digital assets as securities.
- Capital Needs: The company requires additional financing to fund operations and clinical trials; failure to raise capital could force a delay or discontinuation of operations.
Key Facts for Investor Verification
- Listing Status: Verify the company's progress toward regaining Nasdaq compliance by the June 22, 2026 deadline to avoid delisting.
- Crypto Asset Valuation: Confirm the fair value and liquidity of the $221,817 in crypto assets held at fair value and the $98,584 held at cost, noting the impairment losses recognized in 2025.
- License Agreement Status: Review the terms of the new "Termination, Commercial Evaluation License, and Option Agreement" with UMB, which expires March 31, 2026, and the implications for the SPU-16 (Multiple Sclerosis) program.
- Cash Burn Rate: Monitor the net cash used in operating activities ($4.66 million in 2025) against the current cash balance to assess runway duration.
- Equity Dilution: Note the significant number of outstanding warrants (10.2 million) and options (522,850) which could result in substantial dilution upon exercise.